Beijing, Shanghai, Boston, September 26, 2024 – Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it received IND (investigative new drug) approval from the China CDE. Previously, Jacobio has received the IND approval from U.S. FDA. Jacobio plans to initiate phase I/IIa clinical trial in advanced solid tumor patients in China and the U.S.  

KRAS is widely present in a variety of tumor mutations. 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from Pan-KRAS inhibitor. 

JAB-23E73 can inhibit both the active (“ON”）and inactive (“OFF”) states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data showed good pharmacokinetic profile. 

About Jacobio 

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.